Skip to main content

Indaptus Therapeutics, Inc.

INDP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001857044

No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q3 2026, worth $2.18M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$433.2M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +12 vs. previous quarter
21
13F valueReported value at the end of Q3 2026
$2.18M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$20.8M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.14M
Shares sold short
Change
+282.6K
+33.0% vs. previous
Days to cover
3.96
At average daily volume

Superinvestors holding INDP, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding INDP at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Indaptus Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 24, 2026 (view filing)Mar 231 dayLazar David E.DirectorSSale−108.9M–––0 afterDerivative2 lots
Aug 16, 2023 (view filing)Aug 10-146 daysLateAnderson Glen R.10% OwnerPPurchase+103.4K$2.09+$216.4K+9.5%1.19M after3 lots
Dec 19, 2022 (view filing)Jan 31-Dec 1322 daysLateLitchev Boyan VesselinovChief Medical OfficerPPurchase+1.15K$2.19+$2.52KNew position1.15K after4 lots
Nov 22, 2022 (view filing)Nov 18-214 daysMeckler Jeffrey ACEO and DirectorPPurchase+10.0K$1.89+$18.9K+15.3%75.4K after2 lots
Sep 12, 2022 (view filing)Sep 84 daysMeckler Jeffrey ACEO and DirectorPPurchase+10.3K$2.80+$28.9K+18.7%65.4K after
Sep 9, 2022 (view filing)Sep 72 daysLinscott Walt AddisonChief Business OfficerPPurchase+150$2.62+$393New position150 after
Sep 8, 2022 (view filing)Sep 6-72 daysMeckler Jeffrey ACEO and DirectorPPurchase+9.69K$2.56+$24.8K+21.4%55.1K after2 lots
Jun 7, 2022 (view filing)Jun 61 dayMeckler Jeffrey ACEO and DirectorPPurchase+19.7K$2.63+$51.9K+76.9%45.4K after
Feb 2, 2022 (view filing)Jan 31-Feb 12 daysNewman Michael JamesCSO and DirectorSSale−20.0K$5.00−$100.0K−1.4%1.37M after2 lots
Nov 19, 2021 (view filing)Nov 181 dayMeckler Jeffrey ACEO and DirectorPPurchase+11.2K$5.82+$65.1K+77.4%25.6K after

Top 10 13F holders, Q3 2026

See all 21 holders

The largest institutional positions in Indaptus Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding INDP in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Geode Capital Management, LLC195,620$449.9K0.00%+139,150+246.4%Added
Vanguard Capital Management LLC135,978$312.7K0.00%+102,326+304.1%Added
Jane Street Group, LLC86,484$198.9K0.00%+32,673+60.7%Added
UBS Group AG83,363$191.7K0.00%+82,885+17,340.0%Added
Marshall Wace, LLP77,847$179.0K0.00%+77,847New
Millennium Management LLC72,073$165.8K0.00%+60,487+522.1%Added
Vanguard Fiduciary Trust Co65,315$150.2K0.00%+51,348+367.6%Added
State Street Corp63,866$146.9K0.00%+63,866New
Virtu Financial LLC34,659$80.0K0.00%+34,659New
Jump Financial, LLC27,662$63.6K0.00%+27,662New

Holders of 5% or more of INDP

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Indaptus Therapeutics, Inc..

Largest holders of INDP from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Lazar David E.13D/A47.93%2.06M shares−50.07 ppfrom 98.00%Mar 2, 20262 filingsMar 24, 2026SEC
Yao Yun13D/A27.34%42.0M shares−4.17 ppfrom 31.51%Mar 30, 20264 filingsOct 22, 2026SEC
Sino Lion Ventures Ltd13D/A25.32%38.9M shares−3.87 ppfrom 29.19%Jun 26, 20262 filingsOct 22, 2026SEC
Meckler Jeffrey A13D/A12.70%273.1K shares–Oct 10, 20243 filingsDec 30, 2025SEC
Dai Junyi13D/A7.33%11.3M shares−1.11 ppfrom 8.44%Jun 26, 20262 filingsOct 22, 2026SEC